Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Melanoma
  Free Subscription

Articles published in
Cancer Res
    June 2026
  1. AMBROSINI G, Do C, Tycko B, Realubit RB, et al
    Editor's Note: Inhibition of NF-kappaB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
    Cancer Res. 2026;86:3092.
    >> Share

  2. YEVDASH JI, Robinson D, Moore R, Li Z, et al
    GNAQ Induces Melanomagenesis in Mitfa-Independent Melanocyte Progenitors in a Zebrafish Model of Uveal Melanoma.
    Cancer Res. 2026 Jun 10. doi: 10.1158/0008-5472.CAN-25-5299.
    >> Share

  3. KREUGER IZM, Merkus VA, de Haan S, Schrader AMR, et al
    Spatial Analysis Reveals Gene Expression and Microenvironmental Changes in the Transition of Nevus to Melanoma.
    Cancer Res. 2026 Jun 8. doi: 10.1158/0008-5472.CAN-25-2934.
    >> Share

    May 2026
  4. SRIRAMAREDDY S, Siddarajappa N, Park JS, Nguyen T, et al
    GDF15 Reprograms the Microenvironment to Drive Liver Metastasis of Uveal Melanoma.
    Cancer Res. 2026 May 28. doi: 10.1158/0008-5472.CAN-25-0536.
    >> Share

  5. FOTH M, Kim W, O'Toole K, Murphy B, et al
    Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
    Cancer Res. 2026 May 22. doi: 10.1158/0008-5472.CAN-26-1313.
    >> Share

    March 2026
  6. HU J, Zhang B, Chen J, Huang G, et al
    Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells.
    Cancer Res. 2026;86:1351-1371.
    >> Share

    February 2026
  7. RONDEAU V, Bansal S, Buttigieg MM, Zeng AGX, et al
    Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation.
    Cancer Res. 2026;86:845-857.
    >> Share

  8. XU X, Liu X, Jarajapu V, Neelature Sriramareddy S, et al
    A Multi-Step Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma.
    Cancer Res. 2026 Feb 9. doi: 10.1158/0008-5472.CAN-25-2684.
    >> Share

    January 2026
  9. CHEN PY, Bollag G
    Overcoming the Limits of Inhibition: Mutant-Selective BRAF Degraders.
    Cancer Res. 2026;86:289-291.
    >> Share

  10. KREGER BT, Liang Y, Reilly NM, Spears ME, et al
    CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance.
    Cancer Res. 2026;86:438-452.
    >> Share

    August 2025
  11. FLEM-KARLSEN K, Talty R, McGeary MK, Park K, et al
    Cytotoxic CD8+ T Cells Downregulate GPX4 to Promote Ferroptosis in Melanoma that Drives Antitumor Immunity.
    Cancer Res. 2025 Aug 19. doi: 10.1158/0008-5472.CAN-24-1952.
    >> Share

  12. SHAN JL, Zhang KM, Zhong WQ, Yang XY, et al
    Reactivating cGAS-STING Signaling by Targeting SOS1 Enhances Antitumor Immunity in NRAS-Mutant Tumors.
    Cancer Res. 2025;85:3015-3031.
    >> Share

  13. AMBROSINI G, Do C, Tycko B, Realubit RB, et al
    Correction: Inhibition of NF-kappaB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.
    Cancer Res. 2025;85:2954.
    >> Share

    July 2025
  14. CAKSA S, Purwin TJ, Erkes DA, DeRosa KM, et al
    Elevated Transglutaminase-2 in SOX10-Deficient Melanoma Promotes Tumor Onset and Decreases Intratumoral CD4+ T Cells.
    Cancer Res. 2025 Jul 31. doi: 10.1158/0008-5472.CAN-24-3267.
    >> Share

  15. LAIGHT BJ, Harper D, Dmytryk N, Zhang CS, et al
    Fes-Deficient Macrophages Prime CD8+ T Cells to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy.
    Cancer Res. 2025;85:2643-2658.
    >> Share

    June 2025
  16. IBRAHIM M, Illa-Bochaca I, Jour G, Vega-Saenz de Miera E, et al
    NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1 Mutant Melanoma.
    Cancer Res. 2025 Jun 10. doi: 10.1158/0008-5472.CAN-24-3904.
    >> Share

    May 2025
  17. GADAL S, Boyer JA, Roy SF, Outmezguine NA, et al
    Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its Feedback Inhibition of RAC1 and Migration.
    Cancer Res. 2025;85:1611-1627.
    >> Share

    April 2025
  18. SRIVASTAVA J, Yadav VK, Jimenez RV, Phadatare PR, et al
    Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.
    Cancer Res. 2025 Apr 27. doi: 10.1158/0008-5472.CAN-24-0693.
    >> Share

    March 2025
  19. SCORTEGAGNA M, Murad R, Bina P, Feng Y, et al
    Age-Associated Modulation of TREM1/2-Expressing Macrophages Promotes Melanoma Progression and Metastasis.
    Cancer Res. 2025 Mar 24. doi: 10.1158/0008-5472.CAN-24-4317.
    >> Share

  20. MAHURON KM, Shahid O, Sao P, Wu C, et al
    Single Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T Cell Subpopulation that is Correlated with Response to Checkpoint Therapy in Melanoma.
    Cancer Res. 2025 Mar 5. doi: 10.1158/0008-5472.CAN-23-3918.
    >> Share

  21. OSPINA OE, Manjarres-Betancur R, Gonzalez-Calderon G, Soupir AC, et al
    spatialGE Is a User-Friendly Web Application That Facilitates Spatial Transcriptomics Data Analysis.
    Cancer Res. 2025;85:848-858.
    >> Share

    February 2025
  22. ALLARD D, Cormery J, Bricha S, Fuselier C, et al
    Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis.
    Cancer Res. 2025;85:692-703.
    >> Share

    December 2024
  23. RUBINSTEIN JC, Domanskyi S, Sheridan TB, Sanderson B, et al
    Spatiotemporal Profiling Defines Persistence and Resistance Dynamics During Targeted Treatment of Melanoma.
    Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-24-0690.
    >> Share

  24. NASCENTES MELO LM, Sabatier M, Ramesh V, Szylo KJ, et al
    Selenoprotein O Promotes Melanoma Metastasis and Regulates Mitochondrial Complex II Activity.
    Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-23-2194.
    >> Share

  25. FORD CA, Koludrovic D, Centeno PP, Foth M, et al
    Targeting the PREX2/RAC1/PI3Kbeta Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma.
    Cancer Res. 2024 Dec 5. doi: 10.1158/0008-5472.CAN-23-2814.
    >> Share

    November 2024
  26. ZHOU Y, Pang L, Ding T, Chen K, et al
    Precise In Situ Delivery of a Photo-Enhanceable Inflammasome-Activating Nanovaccine Activates Anticancer Immunity.
    Cancer Res. 2024;84:3834-3847.
    >> Share

  27. IZAR B, Kim M
    Peritumoral Venous Vessels: Autobahn and Portal for T cells to Melanoma Brain Metastasis.
    Cancer Res. 2024 Nov 8. doi: 10.1158/0008-5472.CAN-24-4054.
    >> Share

  28. JASANI N, Xu X, Posorske B, Kim Y, et al
    PHGDH Induction by MAPK is Essential for Melanoma Formation and Creates an Actionable Metabolic Vulnerability.
    Cancer Res. 2024 Nov 4. doi: 10.1158/0008-5472.CAN-24-2471.
    >> Share

    October 2024
  29. BOUKERCHE H, Su ZZ, Emdad L, Sarkar D, et al
    Retraction: mda-9/Syntenin Regulates the Metastatic Phenotype in Human Melanoma Cells by Activating Nuclear Factor-kappaB.
    Cancer Res. 2024;84:3312.
    >> Share

    September 2024
  30. LI Y, Ming R, Zhang T, Gao Z, et al
    TCTN1 Induces Fatty Acid Oxidation to Promote Melanoma Metastasis.
    Cancer Res. 2024 Sep 26. doi: 10.1158/0008-5472.CAN-24-0158.
    >> Share

  31. OKADA M, Yamasaki S, Nakazato H, Hirahara Y, et al
    ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.
    Cancer Res. 2024;84:2792-2805.
    >> Share

    July 2024
  32. ENRIQUEZ JA, Mittelbrunn M
    Warburg Effect Reshapes Tumor Immunogenicity.
    Cancer Res. 2024;84:2043-2045.
    >> Share

    June 2024
  33. OATMAN N, Gawali MV, Congrove S, Caceres R, et al
    A multimodal drug-diet-immunotherapy combination restrains melanoma progression and metastasis.
    Cancer Res. 2024 Jun 17. doi: 10.1158/0008-5472.CAN-23-1635.
    >> Share

    May 2024
  34. LIU D, Wei B, Liang L, Sheng Y, et al
    The Circadian Clock Component RORA Increases Immunosurveillance in Melanoma by Inhibiting PD-L1 Expression.
    Cancer Res. 2024 May 8. doi: 10.1158/0008-5472.CAN-23-3942.
    >> Share

    April 2024
  35. FRITSCH EF, Ott PA
    Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence from Mice to Humans.
    Cancer Res. 2024;84:953-955.
    >> Share

    January 2024
  36. XU X, Bok I, Jasani N, Wang K, et al
    PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis.
    Cancer Res. 2024 Jan 9:OF1-OF17. doi: 10.1158/0008-5472.CAN-23-1730.
    >> Share

    November 2023
  37. TAO H, Jin C, Zhou L, Deng Z, et al
    PRMT1 inhibition activates the interferon pathway to potentiate antitumor immunity and enhance checkpoint blockade efficacy in melanoma.
    Cancer Res. 2023 Nov 22. doi: 10.1158/0008-5472.CAN-23-1082.
    >> Share

    October 2023
  38. BIEBERICH F, Reddy ST
    The Unexpected Benefit of TCR Cross-Reactivity in Cancer Immunotherapy.
    Cancer Res. 2023;83:3168-3169.
    >> Share

    September 2023
  39. FERRETTI LP, Bohi F, Leslie Pedrioli DM, Cheng PF, et al
    Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma.
    Cancer Res. 2023 Sep 20. doi: 10.1158/0008-5472.CAN-23-0485.
    >> Share

  40. SHI J, Jiao T, Guo Q, Weng W, et al
    A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug conjugate for targeting melanoma.
    Cancer Res. 2023 Sep 5. doi: 10.1158/0008-5472.CAN-23-1356.
    >> Share

    June 2023
  41. ADAKU N, Ostendorf BN, Mei W, Tavazoie SF, et al
    Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression.
    Cancer Res. 2023 Jun 19:CAN-23-1252. doi: 10.1158/0008-5472.CAN-23-1252.
    >> Share

    May 2023
  42. KIM D, An L, Moon J, Maymi VI, et al
    Ccr2+ monocyte-derived macrophages influence trajectories of acquired therapy resistance in Braf-mutant melanoma.
    Cancer Res. 2023 May 17:CAN-22-2841. doi: 10.1158/0008-5472.CAN-22-2841.
    >> Share

    April 2023
  43. PARK HR, Shiva A, Cummings P, Kim S, et al
    Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma.
    Cancer Res. 2023 Apr 24:CAN-22-2838. doi: 10.1158/0008-5472.CAN-22-2838.
    >> Share

    March 2023
  44. EICHHOFF OM, Stoffel CI, Kasler J, Briker L, et al
    ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.
    Cancer Res. 2023 Mar 22:OF1-OF19. doi: 10.1158/0008-5472.CAN-22-1826.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016